TuHURA Biosciences (HURA) Net Income towards Common Stockholders (2010 - 2026)

TuHURA Biosciences' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at -$7.5 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 13.08% year-over-year to -$7.5 million; the TTM figure through Mar 2026 stood at -$30.9 million (up 7.46% YoY), while the FY2025 annual figure was -$30.1 million, down 32.72% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$7.5 million, down from -$6.8 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $4.7 million in Q2 2023, with the low at -$16.7 million in Q3 2024.
• The 5-year median for Net Income towards Common Stockholders is -$5.8 million (2022), against an average of -$5.6 million.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders surged 233300.0% in 2023, then slumped 430.82% in 2024.
• TuHURA Biosciences' Net Income towards Common Stockholders stood at -$3.5 million in 2022, then fell by 20.43% to -$4.2 million in 2023, then slumped by 300.09% to -$16.7 million in 2024, then jumped by 59.38% to -$6.8 million in 2025, then retreated by 11.46% to -$7.5 million in 2026.
• Business Quant data shows HURA's Net Income towards Common Stockholders at -$7.5 million in Q1 2026, -$6.8 million in Q4 2025, and -$7.1 million in Q3 2025.